Infex Therapeutics is a leading anti-infectives specialist, with a broad
and diverse pipeline of innovative best-in-class and first-in-class drug candidates to address the
urgent global shortage of novel anti-infective treatments.
The Company is building a differentiated pipeline through in-house drug
discovery, acquisition, co-development and in-licensing of early stage/pre-clinical candidates,
developing them to clinical proof of concept before licensing to commercial pharma
partners
